secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0000950170-25-038737
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025
--------------------------------------------------------------------------------

- Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).
- Cash, cash equivalents and marketable securities $313.4M as of Dec 31, 2024; cash runway into mid-2027.
- R&D expenses $20.7M in Q4 2024 ($17.9M Q4 2023); full year $80.8M ($64.6M FY2023).
- ELVN-001 Phase 1 data expected mid-2025; ELVN-002 Phase 1 data expected H2 2025; FDA orphan drug designation.
- First patient dosed in Japanese Phase 1 trial for ELVN-001; ELVN-002 combination trials enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/0000950170-25-038737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/elvn-20250313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer